Collegium Pharmaceutical, Inc. carries a market capitalization of 1.13B, placing it among publicly traded companies globally. Its enterprise value stands at 1.44B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.13B |
| Enterprise Value | 1.44B |
Collegium Pharmaceutical, Inc. currently has 32.41M shares outstanding.
| Shares Outstanding | 32.41M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Collegium Pharmaceutical, Inc. trades at a trailing price-to-earnings ratio of 14.02. The price-to-sales ratio is 1.32, and the price-to-book ratio stands at -12.14.
| PE Ratio | 14.02 |
| PS Ratio | 1.32 |
| PB Ratio | -12.14 |
| P/TBV Ratio | -2.35 |
| P/FCF Ratio | 3.95 |
| P/OCF Ratio | 3.17 |
On an enterprise value basis, Collegium Pharmaceutical, Inc. trades at an EV/EBITDA multiple of 3.47 and an EV/FCF ratio of 3.73. The EV/Sales ratio of 1.80 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 7.63 provides insight into valuation relative to core operating earnings.
| EV / Sales | 1.80 |
| EV / EBITDA | 3.47 |
| EV / EBIT | 7.63 |
| EV / FCF | 3.73 |
Collegium Pharmaceutical, Inc. maintains a current ratio of 1.71, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 258.64, indicating elevated leverage, while an interest coverage ratio of 5.35 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 1.71 |
| Quick Ratio | 1.50 |
| Debt / Equity | 258.64 |
| Debt / EBITDA | 1.95 |
| Interest Coverage | 5.35 |
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | 4.57 |
| Return on Invested Capital (ROIC) | 11.69 |
| Return on Capital Employed (ROCE) | 18.31 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 7.83 |
Over the trailing twelve months, Collegium Pharmaceutical, Inc. has paid 33.29M in income taxes, reflecting an effective tax rate of 30.75.
| Income Tax | 33.29M |
| Effective Tax Rate | 30.75 |
Collegium Pharmaceutical, Inc.'s stock has gained approximately 9.73451% over the past 52 weeks. The 50-day moving average sits at 34.71, while the 200-day moving average is 39.24.
| Beta (5Y) | N/A |
| 52-Week Price Change | 9.73451% |
| 50-Day Moving Average | 34.71 |
| 200-Day Moving Average | 39.24 |
| Average Volume (20 Days) | N/A |
Over the trailing twelve months, Collegium Pharmaceutical, Inc. generated 796.33M in revenue and converted that into 74.95M in net income, yielding earnings per share of 1.89. EBITDA reached 413.90M, while operating income came in at 188.45M.
| Revenue | 796.33M |
| Gross Profit | 483.18M |
| Operating Income | 188.45M |
| Pretax Income | 108.24M |
| Net Income | 74.95M |
| EBITDA | 413.90M |
| EBIT | 188.45M |
| Earnings Per Share (EPS) | 1.89 |
Collegium Pharmaceutical, Inc. holds 421.75M in cash and equivalents against 808.06M in total debt, resulting in a net debt position of 534.17M. Total book value stands at -86.59M, with working capital of 310.70M providing operational flexibility.
| Cash & Cash Equivalents | 421.75M |
| Total Debt | 808.06M |
| Net Debt | 534.17M |
| Equity (Book Value) | -86.59M |
| Book Value Per Share | -2.72 |
| Working Capital | 310.70M |
Collegium Pharmaceutical, Inc. produced 331.04M in operating cash flow over the past twelve months. After subtracting -1.21M in capital expenditures, free cash flow totaled 329.83M - equivalent to 10.38 per share.
| Operating Cash Flow | 331.04M |
| Capital Expenditures | -1.21M |
| Free Cash Flow | 329.83M |
| FCF Per Share | 10.38 |
Collegium Pharmaceutical, Inc. operates with a gross margin of 60.68, reflecting its pricing power and cost economics. The operating margin of 23.66 and net profit margin of 9.41 provide insight into operational efficiency.
| Gross Margin | 60.68 |
| Operating Margin | 23.66 |
| Pretax Margin | 13.59 |
| Profit Margin | 9.41 |
| EBITDA Margin | 51.98 |
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 10.12 |
| FCF Yield | 25.33 |
Collegium Pharmaceutical, Inc. posts an Altman Z-Score of 2.34, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.34 |